OTCMKTS:PFSCF ProMetic Life Sciences (PFSCF) Stock Price, News & Analysis $5.47 0.00 (0.00%) As of 11/18/2019 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About ProMetic Life Sciences Stock (OTCMKTS:PFSCF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ProMetic Life Sciences alerts:Sign Up Key Stats Today's Range$5.47▼$5.4750-Day Range$5.47▼$5.4752-Week Range$5.47▼$352.00VolumeN/AAverage Volume279 shsMarket Capitalization$127.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ProMetic Life Sciences Inc. is a Canadian-based biotechnology company specializing in the discovery, development and commercialization of small-molecule drugs and biologics for the treatment of serious diseases. Headquartered in Laval, Québec, ProMetic leverages proprietary purification technologies—most notably its hydrophobic interaction chromatography platform—to advance both in-house therapeutic candidates and contract development projects for pharmaceutical and biotech clients around the world. The company’s R&D pipeline focuses on fibrotic and metabolic disorders. Its lead compound, PBI-4050, is an orally administered small molecule being evaluated for indications such as idiopathic pulmonary fibrosis and systemic sclerosis. In addition, ProMetic is developing PBI-4547 for non-alcoholic steatohepatitis (NASH) and other metabolic diseases. These programs are supported by preclinical and clinical development teams operating in North America and Europe. Beyond its internal pipeline, ProMetic offers contract development and manufacturing (CDMO) services, providing process development, scale-up and cGMP manufacturing support for plasma-derived and recombinant proteins. The company’s bioprocessing facilities in Québec and subsidiary operations in France serve a diverse roster of global clients, delivering customized purification solutions that address critical bottlenecks in downstream manufacturing. Under the leadership of CEO Eric Althoff and a senior management team with decades of combined experience in pharmaceutical development, ProMetic Life Sciences continues to strengthen its platform capabilities while advancing late-stage programs toward regulatory milestones. The company’s integrated model aims to generate proprietary value through its pipeline while sustaining growth via service revenues from its CDMO business.AI Generated. May Contain Errors. Read More Receive PFSCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProMetic Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PFSCF Stock News HeadlinesThere's Been No Shortage Of Growth Recently For TMC Life Sciences Berhad's (KLSE:TMCLIFE) Returns On CapitalJanuary 28, 2023 | finance.yahoo.comIndia's Glenmark Life Sciences Q3 profit rises 1% on API strengthJanuary 28, 2023 | reuters.comBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change. July 9 at 2:00 AM | Crypto 101 Media (Ad)Here's what to expect from Prometic Life Sciences's earnings reportMay 10, 2022 | markets.businessinsider.comSee More Headlines PFSCF Stock Analysis - Frequently Asked Questions How have PFSCF shares performed this year? ProMetic Life Sciences' stock was trading at $5.4670 at the beginning of the year. Since then, PFSCF shares have increased by 0.0% and is now trading at $5.4670. How do I buy shares of ProMetic Life Sciences? Shares of PFSCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:PFSCF Previous SymbolNASDAQ:PFSCF CIKN/A Webwww.prometic.com Phone1-450-781-0115FaxN/AEmployees50Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$150.73 million Net Margins-894.02% Pretax MarginN/A Return on Equity-3,350.55% Return on Assets-67.76% Debt Debt-to-Equity RatioN/A Current Ratio0.95 Quick Ratio0.71 Sales & Book Value Annual Sales$36.55 million Price / Sales3.49 Cash FlowN/A Price / Cash FlowN/A Book Value($67.63) per share Price / Book-0.08Miscellaneous Outstanding Shares23,313,000Free FloatN/AMarket Cap$127.45 million OptionableNot Optionable Beta2.46 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (OTCMKTS:PFSCF) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMetic Life Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProMetic Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.